Target intelligence / Profile preview

HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat pocket (gp41 NHR pocket)

Target
gp41 NHR pocket
Molecular classification
Viral fusion protein, Type I transmembrane glycoprotein, Envelope protein
01

Overview

The HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat (NHR) deep pocket is a highly conserved hydrophobic cavity essential for the viral entry process (Chan et al., 1997; PMID: 9160751). During HIV-1 infection, the gp41 subunit mediates the fusion between the viral envelope and the host cell plasma membrane. This process involves a dramatic conformational change where three NHR helices form a trimeric coiled-coil, creating three longitudinal grooves that each contain a deep pocket (Liu et al., 2002; PMID: 11752710). The C-terminal heptad repeat (CHR) region of gp41 then folds back into these grooves, with its pocket-binding domain (PBD) inserting into the NHR deep pocket to form a stable six-helix bundle (6-HB). This 6-HB formation brings the viral and cellular membranes into close proximity, facilitating fusion. Because the NHR deep pocket is critical for 6-HB stability and is highly conserved across diverse HIV-1 strains, it serves as a primary target for fusion inhibitors (He et al., 2008; PMID: 18234671). Therapeutic agents, including second-generation peptides like Albuvirtide and various small-molecule inhibitors, are designed to occupy this pocket, thereby preventing the NHR-CHR interaction and blocking viral entry (Zhang et al., 2016; PMID: 27010161).

Other names
gp41 deep pocketgp41 hydrophobic pocketNHR deep pocketgp41 fusion pocketNHR-CHR interface pocket
02

Mechanism of action

Inhibition of six-helix bundle (6-HB) formation by competitively binding to the NHR deep pocket, preventing the interaction between the NHR and CHR regions of gp41.

03

Biological functions

Viral entryMembrane fusionHost-pathogen interaction
04

Disease associations

HIV-1 infectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Injection site reactionsDevelopment of drug resistanceLow oral bioavailabilityHigh cost of production
06

Interacting drugs

Albuvirtide

6 more in the full profile.

07

Biomarkers

HIV-1 RNA viral loadCD4+ T-cell countgp41 resistance mutations

Beyond the preview

Go deeper on HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat pocket (gp41 NHR pocket).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 envelope glycoprotein gp41 N-terminal heptad repeat pocket (gp41 NHR pocket).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call